Prelude Therapeutics Inc
PRLD0.831USD
+0.003+0.33%
Horário de mercado （ET）Cotações atrasadas em 15 min
46.91MValor de mercado
PerdaP/L TTM
Mais detalhes de Prelude Therapeutics Inc Empresa
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.
Informações da empresa
Código da empresaPRLD
Nome da EmpresaPrelude Therapeutics Inc
Data de listagemSep 25, 2020
CEODr. Krishna (Kris) Vaddi, Ph.D.
Número de funcionários131
Tipo de títulosOrdinary Share
Fim do ano fiscalSep 25
Endereço175 Innovation Boulevard
CidadeWILMINGTON
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal19805
Telefone13024671280
Sitehttps://preludetx.com/
Código da empresaPRLD
Data de listagemSep 25, 2020
CEODr. Krishna (Kris) Vaddi, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Krishna (Kris) Vaddi, Ph.D.
Dr. Krishna (Kris) Vaddi, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
3.67M
+29.33%
Dr. Paul A. Friedman, M.D.
Dr. Paul A. Friedman, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
500.10K
--
Dr. Andrew P. Combs, Ph.D.
Dr. Andrew P. Combs, Ph.D.
Chief Chemistry Officer
Chief Chemistry Officer
480.12K
+27.99%
Dr. Peggy A. Scherle, Ph.D.
Dr. Peggy A. Scherle, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
185.69K
+2.77%
Dr. Jane Huang, M.D.
Dr. Jane Huang, M.D.
President, Chief Medical Officer
President, Chief Medical Officer
90.27K
+7.15%
Ms. Mardi C. Dier
Ms. Mardi C. Dier
Independent Director
Independent Director
10.00K
--
Dr. Paul Scherer, M.D.
Dr. Paul Scherer, M.D.
Independent Director
Independent Director
--
--
Dr. Victor Sandor, M.D.
Dr. Victor Sandor, M.D.
Independent Director
Independent Director
--
--
Mr. Bryant D. Lim, J.D.
Mr. Bryant D. Lim, J.D.
Chief Financial Officer, Chief Legal Officer, Corporate Secretary
Chief Financial Officer, Chief Legal Officer, Corporate Secretary
--
--
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Krishna (Kris) Vaddi, Ph.D.
Dr. Krishna (Kris) Vaddi, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
3.67M
+29.33%
Dr. Paul A. Friedman, M.D.
Dr. Paul A. Friedman, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
500.10K
--
Dr. Andrew P. Combs, Ph.D.
Dr. Andrew P. Combs, Ph.D.
Chief Chemistry Officer
Chief Chemistry Officer
480.12K
+27.99%
Dr. Peggy A. Scherle, Ph.D.
Dr. Peggy A. Scherle, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
185.69K
+2.77%
Dr. Jane Huang, M.D.
Dr. Jane Huang, M.D.
President, Chief Medical Officer
President, Chief Medical Officer
90.27K
+7.15%
Ms. Mardi C. Dier
Ms. Mardi C. Dier
Independent Director
Independent Director
10.00K
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: dom, 27 de jul
Atualizado em: dom, 27 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
OrbiMed Advisors, LLC
25.02%
Baker Bros. Advisors LP
23.20%
Vaddi (Krishna)
8.41%
Boxer Capital Management, LLC
4.83%
The Vanguard Group, Inc.
2.31%
Other
36.22%
Investidores
Investidores
Proporção
OrbiMed Advisors, LLC
25.02%
Baker Bros. Advisors LP
23.20%
Vaddi (Krishna)
8.41%
Boxer Capital Management, LLC
4.83%
The Vanguard Group, Inc.
2.31%
Other
36.22%
Tipos de investidores
Investidores
Proporção
Hedge Fund
31.09%
Private Equity
25.02%
Individual Investor
11.38%
Investment Advisor
9.38%
Investment Advisor/Hedge Fund
3.57%
Research Firm
0.70%
Venture Capital
0.06%
Bank and Trust
0.04%
Pension Fund
0.01%
Other
18.77%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
158
35.42M
81.22%
-13.38M
2025Q1
169
35.41M
81.20%
-13.64M
2024Q4
176
41.97M
99.49%
-4.74M
2024Q3
176
39.67M
94.09%
-11.21M
2024Q2
173
43.50M
103.37%
-2.47M
2024Q1
184
38.12M
90.60%
-8.41M
2023Q4
190
38.61M
71.39%
-9.45M
2023Q3
202
40.53M
76.60%
-4.90M
2023Q2
201
43.54M
105.11%
+2.58M
2023Q1
203
37.45M
102.57%
-2.14M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
OrbiMed Advisors, LLC
10.91M
25.02%
--
--
Mar 31, 2025
Baker Bros. Advisors LP
10.12M
23.2%
-5.19K
-0.05%
Jun 12, 2025
Vaddi (Krishna)
3.67M
8.41%
+832.02K
+29.33%
Mar 31, 2025
Boxer Capital Management, LLC
2.11M
4.83%
+399.83K
+23.41%
Mar 31, 2025
The Vanguard Group, Inc.
1.01M
2.31%
-1.19K
-0.12%
Mar 31, 2025
T. Rowe Price Associates, Inc.
959.30K
2.2%
-53.05K
-5.24%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
919.00K
2.11%
-14.36K
-1.54%
Mar 31, 2025
Renaissance Technologies LLC
656.70K
1.51%
+22.20K
+3.50%
Mar 31, 2025
Acadian Asset Management LLC
529.33K
1.21%
+43.95K
+9.05%
Mar 31, 2025
Friedman (Paul A)
500.10K
1.15%
--
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Dimensional US Core Equity 1 ETF
0%
iShares Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
ProShares Ultra Nasdaq Biotechnology
0%
Schwab U.S. Small-Cap ETF
0%
Schwab U.S. Broad Market ETF
0%
iShares Micro-Cap ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Ver Mais
Dimensional US Core Equity 1 ETF
Proporção0%
iShares Russell 2000 ETF
Proporção0%
Proshares Ultra Russell 2000
Proporção0%
ProShares UltraPro Russell2000
Proporção0%
ProShares Ultra Nasdaq Biotechnology
Proporção0%
Schwab U.S. Small-Cap ETF
Proporção0%
Schwab U.S. Broad Market ETF
Proporção0%
iShares Micro-Cap ETF
Proporção0%
Invesco Nasdaq Biotechnology ETF
Proporção0%
iShares Core S&P Total U.S. Stock Market ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
